Posted by Michael Wonder on 09 Dec 2020
BeiGene announces the approval in China of Blincyto (blinatumomab) for injection for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
7 December 2020 - BeiGene today announced that the China NMPA has approved Blincyto (blinatumomab) for injection for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.
The biologics license application had been submitted by Amgen and received priority review by the Center for Drug Evaluation of the NMPA.
